OTCMKTS:WILYY Demant A/S (WILYY) Stock Price, News & Analysis $18.05 0.00 (0.00%) As of 05/19/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesShort InterestBuy This Stock About Demant A/S Stock (OTCMKTS:WILYY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Demant A/S alerts:Sign Up Key Stats Today's Range$18.05▼$18.0550-Day Range$13.45▼$18.3052-Week Range$13.45▼$21.93Volume18 shsAverage Volume191 shsMarket Capitalization$7.64 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions. Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division. The group also offers accessories and wireless connectivity products that integrate with smartphones and assistive listening devices. Demant’s focus on research and innovation is reflected in its investment in digital platforms and signal-processing technologies aimed at improving speech clarity and user comfort. Headquartered in Smørum, Denmark, Demant serves customers in more than 130 countries through a network of subsidiaries, distributors and partner clinics. The company operates manufacturing facilities across Europe and Asia, and maintains regional offices in North America and the Asia Pacific to support local markets. Its global presence allows Demant to address diverse regulatory environments and cater to a wide range of clinical practices and consumer preferences. Founded in 1904 by entrepreneur Hans Demant under the Oticon name, the company was reorganized into the Demant Group and publicly listed in 1995. Over its history, Demant has grown through strategic acquisitions and internal development, reinforcing its position in the hearing health industry. The organization is led by President & CEO Søren Nielsen, supported by an executive leadership team that oversees ongoing innovation, quality assurance and expansion into emerging markets.AI Generated. May Contain Errors. Read More Demant A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreWILYY MarketRank™: Demant A/S scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingBuy Consensus RatingDemant A/S has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDemant A/S has only been the subject of 1 research reports in the past 90 days.Read more about Demant A/S's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioDemant A/S has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Demant A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Demant A/S has been sold short.Short Interest Ratio / Days to CoverDemant A/S has a short interest ratio ("days to cover") of 0.17, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDemant A/S does not currently pay a dividend.Dividend GrowthDemant A/S does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Demant A/S this week, compared to 0 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Demant A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsDemant A/S has minimal institutional ownership at this time.Read more about Demant A/S's insider trading history. Receive WILYY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Demant A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WILYY Stock News HeadlinesReviewing Demant A/S (OTCMKTS:WILYY) & Maravai LifeSciences (NASDAQ:MRVI)4 hours ago | americanbankingnews.comDemant shares surge 15% after Oticon Zeal drives Q1 growthMay 7, 2026 | za.investing.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 21 at 1:00 AM | Weiss Ratings (Ad)Demant A/S: Expansion of Demant's Executive Leadership TeamMay 6, 2026 | finanznachrichten.deJefferies flips on hearing aid giants, upgrades Demant, cuts SonovaMarch 18, 2026 | investing.com3 European Stocks Estimated To Be Trading At Over 49.3% Below Intrinsic ValueFebruary 18, 2026 | finance.yahoo.comDemant tops Q4 forecasts on Diagnostics recovery, but shares tumble on outlookFebruary 4, 2026 | investing.comDemant A/S (WILYY) Q4 2025 Earnings Call TranscriptFebruary 3, 2026 | seekingalpha.comSee More Headlines WILYY Stock Analysis - Frequently Asked Questions How have WILYY shares performed this year? Demant A/S's stock was trading at $16.39 at the start of the year. Since then, WILYY stock has increased by 10.1% and is now trading at $18.05. How do I buy shares of Demant A/S? Shares of WILYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/21/2026Next Earnings (Estimated)5/27/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED PRODUCTS Sub-IndustryN/A Current SymbolOTCMKTS:WILYY Previous SymbolNASDAQ:WILYY CIKN/A Webwww.demant.com Phone(453) 917-7300Fax45-3927-8900Employees26,704Year Founded1904Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.65 Current Ratio1.36 Quick Ratio1.00 Sales & Book Value Annual Sales$3.48 billion Price / Sales2.20 Cash Flow$0.88 per share Price / Cash Flow20.54 Book Value$3.51 per share Price / Book5.14Miscellaneous Outstanding Shares423,510,000Free FloatN/AMarket Cap$7.64 billion OptionableNot Optionable Beta1.13 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:WILYY) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Demant A/S Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Demant A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.